[go: up one dir, main page]

MX2009010800A - Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. - Google Patents

Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.

Info

Publication number
MX2009010800A
MX2009010800A MX2009010800A MX2009010800A MX2009010800A MX 2009010800 A MX2009010800 A MX 2009010800A MX 2009010800 A MX2009010800 A MX 2009010800A MX 2009010800 A MX2009010800 A MX 2009010800A MX 2009010800 A MX2009010800 A MX 2009010800A
Authority
MX
Mexico
Prior art keywords
fusions
mycobacterium tuberculosis
immunogenic compositions
tuberculosis polypeptides
compositions
Prior art date
Application number
MX2009010800A
Other languages
English (en)
Inventor
Steven G Reed
Rhea N Coler
Gregory C Ireton
Original Assignee
Infectious Disease Res Inst Id
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Res Inst Id filed Critical Infectious Disease Res Inst Id
Publication of MX2009010800A publication Critical patent/MX2009010800A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

La presente invención se refiere a composiciones y proteínas de fusión que contienen por lo menos dos antígenos de Mycobacterium sp, y polinucleótidos que codifican dichas composiciones y proteínas de fusión; la invención también se refiere a métodos para su uso en el tratamiento, prevención y/o diagnóstico de infección de tuberculosis.
MX2009010800A 2007-04-04 2008-04-04 Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. MX2009010800A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91016907P 2007-04-04 2007-04-04
PCT/US2008/059500 WO2008124647A2 (en) 2007-04-04 2008-04-04 Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof

Publications (1)

Publication Number Publication Date
MX2009010800A true MX2009010800A (es) 2010-01-29

Family

ID=39620241

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009010800A MX2009010800A (es) 2007-04-04 2008-04-04 Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
MX2012011371A MX351247B (es) 2007-04-04 2008-04-04 Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012011371A MX351247B (es) 2007-04-04 2008-04-04 Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.

Country Status (11)

Country Link
US (6) US8486414B2 (es)
EP (2) EP3199176B1 (es)
JP (3) JP5378350B2 (es)
CN (2) CN104815324A (es)
BR (1) BRPI0809926B8 (es)
DK (1) DK2136836T3 (es)
ES (1) ES2621211T3 (es)
MX (2) MX2009010800A (es)
PL (1) PL2136836T3 (es)
WO (1) WO2008124647A2 (es)
ZA (1) ZA200907316B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8053181B2 (en) * 2006-03-14 2011-11-08 Oregon Health & Science University Methods for detecting a Mycobacterium tuberculosis infection
JP5378350B2 (ja) 2007-04-04 2013-12-25 インフェクティアス ディジーズ リサーチ インスティチュート 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ）ポリペプチドおよびその融合物を含む免疫原性組成物
EP2501397B1 (en) * 2009-11-20 2017-10-04 Oregon Health and Science University Methods for producing an immune response to tuberculosis
US20130345079A1 (en) * 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
EP2573107A1 (en) * 2011-09-21 2013-03-27 Norwegian Institute of Public Health A recombinant fusion protein
US20140349320A1 (en) * 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
CN102586139B (zh) * 2012-01-20 2013-03-20 广东本科生物工程股份有限公司 一种高产ad/add的菌株及高效生产ad/add的方法
US9404923B2 (en) * 2012-02-07 2016-08-02 Intuitive Biosciences, Inc. Mycobacterium tuberculosis specific peptides for detection of infection or immunization in non-human primates
RS58868B1 (sr) 2012-02-07 2019-08-30 Infectious Disease Res Inst Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
US10048561B2 (en) 2013-02-21 2018-08-14 View, Inc. Control method for tintable windows
EP2872172B1 (en) * 2012-07-10 2018-11-14 Transgene SA Mycobacterial antigen vaccine
PT2879701T (pt) * 2012-08-03 2024-02-12 Access To Advanced Health Inst Composições e métodos para o tratamento de uma infeção ativa por mycobacterium tuberculosis
CN102899334B (zh) * 2012-10-29 2015-02-25 英诺特（唐山）生物技术有限公司 一种结核分枝杆菌重组蛋白质及其制备方法
US9789175B2 (en) 2013-03-15 2017-10-17 The Trustees Of The University Of Pennsylvania Synthetic immunogens for prophylaxis or treatment of tuberculosis
CN104237508B (zh) * 2013-06-19 2015-12-02 华中农业大学 一种结核分枝杆菌的检测试剂盒及应用
CN104237509B (zh) * 2013-06-19 2015-12-02 华中农业大学 一种结核分枝杆菌的检测试剂盒及应用
CN105431166B (zh) 2013-06-25 2020-09-18 国际艾滋病疫苗行动组织公司 结核病组合物和其使用方法
TWI654200B (zh) * 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
JP6249712B2 (ja) * 2013-10-09 2017-12-20 公益財団法人ヒューマンサイエンス振興財団 非傍腫瘍性急性脳炎患者の予後診断装置の作動方法
CN103698531B (zh) * 2013-11-25 2015-10-14 广东体必康生物科技有限公司 Rv1860、Rv0173和/或Rv1812c蛋白在制备诊断活动性肺结核的产品中的用途
IL310015B1 (en) * 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
CA2936131A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
KR101477795B1 (ko) * 2014-04-23 2015-01-02 건국대학교 산학협력단 Ａｄｋ 단백질을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물
SG11201704766UA (en) * 2014-12-10 2017-07-28 Konkuk Univ Glocal Industry-Academic Collaboration Found Antibacterial composition containing adk protein as active ingredient, or composition for preventing or treating septicemia
SG11201708130PA (en) * 2015-04-03 2017-11-29 Konkuk Univ Glocal Industry-Academic Collaboration Foundation Antibacterial composition for combating carbapenem-resistant gram-negative bacteria comprising adk protein as active ingredient
CN106645733A (zh) * 2015-07-16 2017-05-10 广东体必康生物科技有限公司 用于特异性检测结核分枝杆菌感染的蛋白
EP4112638A1 (en) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
JP7195147B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
JP2019521095A (ja) * 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
WO2017210364A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
US10428122B2 (en) 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
US11091775B2 (en) 2016-06-22 2021-08-17 Oregon Health And Science University Recombinant cytomegalovirus vectors as vaccines for tuberculosis
EP3555630B1 (en) 2016-12-14 2023-05-31 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
AU2018285694B2 (en) 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
CN107817228B (zh) * 2017-06-30 2022-06-14 四川农业大学 对E.coli O157:H7免酶及免荧光标记的检测方法
AU2018330165B2 (en) 2017-09-08 2025-07-17 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
US11638749B2 (en) 2017-10-17 2023-05-02 International Aids Vaccine Initiative, Inc. Tuberculosis antigen cassettes
US12195810B2 (en) 2017-12-22 2025-01-14 Massachusetts Eye And Ear Infirmary Comprehensive microbial panel for molecular diagnosis of eye infections
AU2019260805A1 (en) 2018-04-26 2020-11-26 Children's National Medical Center Mycobacterial antigen compositions and methods of use
CN108411030B (zh) * 2018-05-25 2021-05-14 兰州大学 引物对及包含其的试剂盒、用途和检测蒺藜苜蓿生态型a17和r108的方法
CN108948175B (zh) * 2018-07-23 2020-11-20 首都医科大学附属北京胸科医院 与人类蛋白smad2相互作用的结核蛋白及其应用
JP2021535930A (ja) * 2018-09-17 2021-12-23 キュラティス インコーポレイティッド Ｓｔｉｎｇアゴニストを含む抗原性補強剤及びワクチン組成物
KR102524577B1 (ko) * 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도
WO2020222559A1 (ko) * 2019-05-02 2020-11-05 주식회사 엘베이스 신규한 올리고펩티드 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
BR112021025172A2 (pt) * 2019-06-14 2022-01-25 Statens Seruminstitut Proteínas de fusão para vacinas de tuberculose
GB201909953D0 (en) * 2019-07-11 2019-08-28 Sec Dep For Environment Food And Rural Affairs Acting Through The Animal And Plant Health Agency Diagnostic reagents
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
CN111286551A (zh) * 2020-01-04 2020-06-16 昆明理工大学 结核分枝杆菌的快速检测引物、试剂盒及其使用方法
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
JP2024501949A (ja) 2020-12-23 2024-01-17 アクセス ツー アドバンスト ヘルス インスティチュート ソラネソールワクチンアジュバント及びその調製方法
CN113121703B (zh) * 2021-03-03 2023-04-25 上海晶诺生物科技有限公司 一种具有结核杆菌免疫原性的融合蛋白及其应用
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
AU2022351009A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Rna vaccines against infectious diseases
EP4404957A4 (en) 2021-09-22 2025-08-06 Hdt Bio Corp CANCER THERAPY COMPOSITIONS AND THEIR USES
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
CN114150006B (zh) * 2021-11-29 2023-07-25 中国农业科学院植物保护研究所 一种可提高米尔贝霉素产量的基因簇、重组菌及其制备方法与应用
CN116284283A (zh) * 2021-12-13 2023-06-23 江苏瑞科生物技术股份有限公司 重组结核分枝杆菌抗原、其制备方法和应用
AU2023336224A1 (en) 2022-09-09 2025-03-27 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN116041454B (zh) * 2022-12-07 2023-12-26 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因、应用
NL2036756B1 (en) * 2024-01-05 2024-08-29 Univ Shihezi Fluorescent pcr method for detecting listeria monocytogenes and mycobacterium tuberculosis in milk
CN118987197B (zh) * 2024-10-24 2025-01-24 山东第二医科大学 一种自佐剂型热稳定纳米多价结核疫苗及其制备方法与应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4761180A (en) 1986-08-27 1988-08-02 Hewlett-Packard Company Dyes containing tetramethylammonium cation for ink-jet printing inks
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
EP1484405A1 (en) 1997-11-10 2004-12-08 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. Tuberculosis
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20020081579A1 (en) 1998-02-13 2002-06-27 Jane E. R. Potter Method for the isolation of novel antigens
CZ302870B6 (cs) 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
CA2386841A1 (en) 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
AU6867801A (en) 2000-06-20 2002-01-02 Corixa Corp Fusion proteins of mycobacterium tuberculosis
WO2003093307A2 (en) * 2002-04-27 2003-11-13 The Secretary Of State For Environment, Food And Rural Affairs Mycobacterial antigens and uses thereof
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
EP1786460A4 (en) 2004-08-26 2008-04-02 Sequella Inc TEST FOR DETECTION OF TUBERCULOSIS IN NON-MENTAL PRIMATES
WO2006026464A2 (en) * 2004-08-27 2006-03-09 Davidsen Kevin P Handclapping aid
AU2006261445B2 (en) * 2005-06-23 2011-03-31 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
ES2657392T3 (es) 2006-09-26 2018-03-05 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
JP5378350B2 (ja) 2007-04-04 2013-12-25 インフェクティアス ディジーズ リサーチ インスティチュート 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ）ポリペプチドおよびその融合物を含む免疫原性組成物

Also Published As

Publication number Publication date
US20250304629A1 (en) 2025-10-02
US20220017578A1 (en) 2022-01-20
ES2621211T3 (es) 2017-07-03
US20100129391A1 (en) 2010-05-27
MX351247B (es) 2017-10-05
CN101687027A (zh) 2010-03-31
US11897922B2 (en) 2024-02-13
EP2136836B8 (en) 2017-04-12
JP5378350B2 (ja) 2013-12-25
BRPI0809926B8 (pt) 2021-05-25
CN101687027B (zh) 2015-01-28
US8486414B2 (en) 2013-07-16
EP2136836B1 (en) 2017-01-04
EP3199176A1 (en) 2017-08-02
US12344641B2 (en) 2025-07-01
WO2008124647A3 (en) 2009-04-02
EP2136836A2 (en) 2009-12-30
EP3199176B1 (en) 2020-02-19
PL2136836T3 (pl) 2017-07-31
US20180170975A1 (en) 2018-06-21
CN104815324A (zh) 2015-08-05
JP2016145209A (ja) 2016-08-12
JP2014058520A (ja) 2014-04-03
ZA200907316B (en) 2013-03-27
US20130209500A1 (en) 2013-08-15
US11091521B2 (en) 2021-08-17
WO2008124647A2 (en) 2008-10-16
US20240140997A1 (en) 2024-05-02
DK2136836T3 (en) 2017-04-10
BRPI0809926B1 (pt) 2020-09-29
JP5922074B2 (ja) 2016-05-24
US9822152B2 (en) 2017-11-21
JP2010524854A (ja) 2010-07-22
BRPI0809926A2 (pt) 2014-10-07

Similar Documents

Publication Publication Date Title
MX351247B (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
UA107329C2 (uk) Туберкульозний білок rv2386c, композиція, що його містить, та застосування
WO2006082406A3 (en) Human antibodies and proteins
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
MX2007003402A (es) Composicion inmunogena para su uso en vacunacion contra estafilococos.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
EA201001322A1 (ru) Вакцины против хламидиоза
MX2010003574A (es) Anticuerpos il-23.
MX2011006205A (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
EA033007B1 (ru) ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ
MX2010005589A (es) Composicion para el cuidado personal.
DK2054431T3 (da) Konformere af bakterielle adhæsiner
WO2010039224A3 (en) Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
MXPA06010469A (es) Proteina recombinante portadora de epitopos del virus de papiloma humano insertados en una proteina adenilato ciclasa o en un fragmento de ella y sus usos terapeuticos.
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
MX2012004622A (es) Adyuvante para vacunas, vacunas que lo comprenden y usos.
WO2011067758A3 (en) Immunogenic fragments and multimers from streptococcus pneumoniae proteins
MX2007003624A (es) Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas.
WO2008055916A3 (en) New antigens for paratuberculosis diagnosis and vaccination
GB0818080D0 (en) Immunogenic peptides

Legal Events

Date Code Title Description
FG Grant or registration